川芎嗪联合倍他司汀治疗老年后循环缺血性眩晕患者的效果

Efficacy of tetramethylpyrazine combined with betahistine in the treatment of posterior circulation ischemic vertigo in elderly patients

摘要:

目的 分析川芎嗪联合倍他司汀治疗老年后循环缺血性眩晕（PCIV）患者的效果。方法 选取2023年12月至2024年9月九江市第一人民医院收治的86例老年PCIV患者，按随机数字表法分为两组，各43例。对照组行倍他司汀治疗，观察组采用川芎嗪联合倍他司汀治疗。对比两组临床疗效、眩晕严重程度、椎-基底动脉流速、血液流变学、氧化应激反应、不良反应。结果 观察组治疗总有效率为95.35%（41/43），高于对照组的81.40%（35/43）；治疗后，观察组眩晕残障程度评定量表内各维度评分分别为（9.77±1.20）分、（10.53±1.05）分、（11.26±1.57）分，各血液流变学分别为（45.83±4.01）%、（5.41±0.89）mpa·s、（7.01±1.20）mpa·s，丙二醛为（3.19±0.40）mmol/mL，低于对照组的（13.21±1.59）分、（15.27±1.62）分、（16.54±2.01）分、（50.42±4.63）%、（6.21±1.03）mpa·s、（8.95±1.64）mpa·s、（4.25±0.59）mmol/mL，椎-基底动脉流速分别为（31.25±3.42）cm/s、（35.98±4.66）cm/s、（43.58±4.67）cm/s，快于对照组的（27.36±2.59）cm/s、（30.59±3.84）cm/s、（38.77±3.63）cm/s，超氧化物歧化酶为（169.85±13.75）U/L，高于对照组的（145.36±10.56）U/L，有统计学差异（P＜0.05）；两组不良反应对比无统计学差异（P＞0.05）。结论 川芎嗪联合倍他司汀可减轻老年PCIV患者眩晕症状，调节椎-基底动脉流速，改善血液流变学，减轻氧化应激反应，且安全性较好。

Abstract:

Objective To analyze the efficacy of tetramethylpyrazine combined with betahistine in the treatment of posterior circulation ischemic vertigo (PCIV) in elderly patients.Methods A total of 86 elderly patients with PCIV admitted to Jiujiang First People's Hospital from December 2023 to September 2024 were selected and randomly divided into two groups, with 43 patients in each group. The control group was treated with betahistine, while the observation group was treated with tetramethylpyrazine and betahistine. The clinical efficacy, severity of vertigo, vertebrobasilar artery flow velocity, hemorheology, oxidative stress response, and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.35% (41/43), which was higher than that of the control group [81.40% (35/43)]. After treatment, the scores of each dimension in the vertigo disability assessment scale of the observation group were (9.77±1.20) points, (10.53±1.05) points, and (11.26±1.57) points, respectively; The hemorheology values were (45.83±4.01)%, (5.41±0.89) mpa·s, and (7.01±1.20) mpa·s, respectively; The malondialdehyde level was (3.19±0.40) mmol/mL, which were lower than those of the control group [(13.21±1.59) points, (15.27±1.62) points, (16.54±2.01) points, (50.42±4.63)%, (6.21±1.03) mpa·s, (8.95±1.64) mpa·s, and (4.25±0.59) mmol/mL,respectively] . The vertebrobasilar artery flow velocities were (31.25±3.42) cm/s, (35.98±4.66) cm/s, and (43.58±4.67) cm/s, respectively, which were faster than those of the control group [(27.36±2.59) cm/s, (30.59±3.84) cm/s, and (38.77±3.63) cm/s,respectively]. The superoxide dismutase level was (169.85±13.75) U/L, which was higher than that of the control group[(145.36±10.56) U/L], with statistical differences (P＜0.05). There was no difference in adverse reactions between the two groups (P＞0.05).Conclusion Tetramethylpyrazine combined with betahistine can alleviate vertigo symptoms in elderly patients with PCIV, regulate vertebrobasilar artery flow velocities, improve hemorheology, reduce oxidative stress, and has good safety.